iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
Rhea-AI Summary
Insight Molecular Diagnostics (Nasdaq: IMDX) announced management will attend investor conferences during JPM Week and BTIG Snowbird in winter 2026. Key events: LifeSci Advisors 15th Annual Corporate Access Event (one-on-one meetings, Jan 12, The Beacon Grand, San Francisco), additional JPM Week investor meetings (one-on-one, Jan 12–14, San Francisco), and BTIG 13th Annual Snowbird (one-on-one meetings and skiing, Feb 9–11, Cliff Lodge, Snowbird, Utah). The company provided contact instructions for scheduling in-person meetings via LifeSci Partners or BTIG sales representatives.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 06 | Leadership appointment | Positive | -1.1% | Hired VP Medical Affairs to support transplant assay commercialization. |
| Jan 05 | Clinical/regulatory update | Positive | +4.3% | Reported GraftAssureDx de novo work ~95% complete and broad site engagement. |
| Nov 10 | Earnings and pipeline | Positive | +9.0% | Q3 2025 results with GraftAssureDx submission plans and registry build-out. |
| Nov 03 | Earnings pre-announcement | Positive | +1.8% | Set date for Q3 2025 results and highlighted upcoming investor conference. |
| Oct 13 | Leadership appointment | Positive | +4.6% | Named VP Marketing to drive 2026 commercial launch for GraftAssure family. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company updates, especially clinical and earnings-related milestones, have more often coincided with positive price reactions, while some organizational news has seen mild divergence.
Over the past few months, IMDX has steadily advanced its transplant diagnostics franchise. An October 13, 2025 leadership hire to support GraftAssure commercialization saw a 4.62% gain. Pre‑Q3 earnings communication on Nov 3, 2025 was followed by a 1.83% rise, and Q3 results on Nov 10, 2025 with $260,000 lab revenue and a planned 5,000‑participant registry led to an 8.97% move. A January 5, 2026 clinical update produced a 4.33% gain, while a January 6, 2026 medical‑affairs hire coincided with a modest 1.07% decline.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference.
LifeSci Advisors 15th Annual Corporate Access Event
Date: Monday, January 12th
Location: The Beacon Grand, San Francisco, Calif.
Format: One-on-one meetings with management
Additional “JPM Week” Investor Meetings
Date: Monday, January 12th through Wednesday, January 14th
Location: San Francisco, Calif.
Format: One-on-one meetings with management
BTIG 13th Annual Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
Date: February 9th – 11th
Location: Cliff Lodge, Snowbird, Utah
Format: One-on-one meetings and skiing with management
To request an in-person meeting with management on Monday, January 12th, during the week of the 44th Annual J.P. Morgan Healthcare Conference, either register at LifeSci Partners Corporate Access Event 2026 or contact our LifeSci Partners representatives Alexandra Grossman (alex@lifesciadvisors.com). For meetings at the BTIG conference, please contact your sales representative at BTIG.
About Insight Molecular Diagnostics, Inc.
Insight Molecular Diagnostics is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. Investors may visit https://investors.Insight Molecular Diagnostics.com/ for more information.
Investor Contact:
Doug Farrell
LifeSci Advisors LLC
dfarrell@lifesciadvisors.com
